Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
Authors:
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetesJournal of Thrombosis and Haemostasis, 2012
- Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrelJournal of Thrombosis and Haemostasis, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery DiseaseCirculation: Cardiovascular Interventions, 2011
- Diabetes and Antiplatelet Therapy in Acute Coronary SyndromeCirculation, 2011
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregationJournal of Thrombosis and Haemostasis, 2010
- Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trialEuropean Heart Journal, 2010
- Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38Circulation, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993